IN8bio to Present at the H.C. Wainwright Annual Investment Conference
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on developing groundbreaking gamma-delta T cell therapies, has an exciting announcement for investors and stakeholders. William Ho, the CEO and co-founder of IN8bio, will be presenting at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. This presentation will take the form of a fireside chat, where viewers can expect to gain valuable insights into the company’s progress in the field of immunotherapy.
Event Details
The conference is set to occur during a time slot that accommodates a wide audience. Attendees can look forward to the presentation on a Monday afternoon, which will not only delve into the company’s current projects but also outline its future aspirations. A live webcast will be available, allowing for later viewing and broadening access for potential investors and interested parties.
IN8bio's Commitment to Innovation
IN8bio is leading the charge in developing gamma-delta T cell-based immunotherapies tailored for cancer patients. This unique immunotherapy leverages the special abilities of gamma-delta T cells, which have demonstrated exceptional potential in differentiating between healthy cells and diseased tissues. This innovative strategy positions IN8bio as a frontrunner in the fight against cancer, establishing new benchmarks for treatment approaches.
Current Clinical Programs
The company's flagship program, INB-400, is currently in a Phase 2 trial targeting glioblastoma multiforme (GBM), a notably aggressive form of brain cancer. Additionally, IN8bio is progressing with several other programs at various stages of clinical trials for both solid and hematologic tumors. These include INB-200, aimed at GBM, and INB-100 for patients with hematologic malignancies, particularly those preparing for transplantation. This diverse pipeline reflects IN8bio’s strong commitment to addressing urgent cancer treatment needs.
How to Access the Presentation
For those interested in following IN8bio's developments, the company will host a live webcast of the session. After the live event, a replay will be available in the 'Events and Presentations' section of the IN8bio website, making the information shared during the presentation more accessible to a wider audience.
About IN8bio
IN8bio is dedicated to advancing immunotherapy by harnessing the power of gamma-delta T cells to create effective treatments for cancer patients. Their cutting-edge research and clinical trials are paving the way for innovative strategies to tackle complex cancers, offering hope to those who need it most. To find out more about IN8bio and their ongoing initiatives, prospective investors and interested parties can visit www.IN8bio.com.
Contact Information
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH
IN8bio, Inc.
203.494.7411
gdschulman@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
Frequently Asked Questions
What is the focus of IN8bio?
IN8bio specializes in developing gamma-delta T cell therapies aimed at innovating cancer treatment approaches.
When will IN8bio present at the conference?
The presentation is scheduled for a Monday afternoon during H.C. Wainwright's 26th Annual Global Investment Conference.
What is gamma-delta T cell therapy?
This therapy employs a specific subset of T cells that can distinguish between healthy and diseased cells, providing a promising method for treating cancer.
What are the current clinical trials for IN8bio?
IN8bio is conducting several clinical trials, including the INB-400 program in Phase 2 for glioblastoma multiforme, along with other trials targeting solid and hematologic tumors.
How can I access the IN8bio presentation?
The presentation will be available as a live webcast on the IN8bio website, with a replay offered for those who cannot attend the live session.
